At the 2025 SNMMI Annual Meeting, Dr. David Pattison presented Lead-212 as a promising alpha-emitter for radioligand therapy in prostate cancer as part of the CE09: PSMA Theranostics Session (available on demand) and highlighted AdvanCell’s TheraPb and ADVC001.
Presentation was featured in UroToday’s SNMMI 2025 Conference Highlights (link).
212Pb – The Ideal Isotope for Alpha Therapy
Lead-212’s unique characteristics position it as a compelling isotope for alpha-based radioligand therapy, combining a short tissue penetration range and high linear energy transfer (LET) to deliver potent cytotoxicity to cancer cells. Its brief half-life of 10.6 hours and favorable imaging properties further enhance both safety and precise dosimetry. Patient and staff exposure levels are comparable to the established therapies, such as Lutetium-177, with manageable discharge protocols in place.
(Click image to see full size)
ADVC001 as First-In-Class 212Pb-PSMA
A growing number of studies are evaluating Lead-212 across multiple oncology therapeutic areas. In prostate cancer, AdvanCell’s TheraPb (NCT05720130) stands out as the only 212Pb-PSMA therapy in the clinic, presenting a potential first-in-class and best-in-class opportunity.
(Click image to see full size)
TheraPb Case Study
TheraPb Ph1/2 (NCT05720130) is currently enrolling in Australia. The trial is evaluating [212Pb]Pb-ADVC001 in Metastatic Castration Resistance Prostate Cancer (mCRPC). Study design below:
(Click image to see full size)
During the session, Dr. Pattison presented a case study from TheraPb featuring a 77-year-old male with progressive metastatic castration-resistant prostate cancer (mCRPC), who had previously undergone treatment with ADT, enzalutamide, and docetaxel. In the phase 1b dose-escalation portion of the trial, the patient received 160 MBq every four weeks for six cycles. Notably, the case demonstrated a 99% decline in PSMA levels from baseline to six weeks, a marked reduction in lesion size, and only minimal change in salivary gland PSMA uptake.
(Click image to see full size)
The session also highlighted the feasibility of imaging ²¹²Pb using SPECT/CT, along with ongoing efforts to further optimize and refine this technique.
